Fragmentation of Nimotuzumab for Preparation of 125I-F(ab’)2-Nimotuzumab as a Precursor for Preparing 125I-F(ab’)2-Nimotuzumab-NLS Radiopharmaceutical for Cancer Therapy

R.D. Haryuni, A. Bahtiar, S. Soenarjo, Y. Harahap, A. Mutalib, M. Ramli, S. Hermanto, C.N. Ardiyatno, V.Y. Susilo, D. Haffid

Abstract


Nimotuzumab is an anticancer agent which belongs to the inhibitor group of Epidermal Growth Factor Receptor (EGFR). Thismonoclonal antibody has a relatively high molecular weight which slowspenetration on tumor cells, making it less attractive in imaging kinetics and potentially elicits antibodies responses. Therefore, in this study nimotuzumab was fragmented to form a bivalent antibody [F(ab’)2] and then labeled with 125I to form 125I-F(ab’)2-nimotuzumab which can be used further as a precursor for preparing 125I-F(ab’)2-nimotuzumab-NLS(NLS = nuclear localization sequence) radiopharmaceuticalfor radioimmunotherapy. The aims of this study was to obtain  characteristics of 125I-F(ab’)2-nimotuzumab by comparing with the 125I labeled-intact nimotuzumab (125I-nimotuzumab). This study was initiated by purifying nimotuzumab by mean of dialysis. The purified nimotuzumab was then fragmented by using pepsin. The F(ab')2-nimotuzumab formed was then purified from its by-products which formed in fragmentation process by using a PD-10 column (consisted Sephadex G25). The intact nimotuzumab and its F(ab’)2 fragment were then labeled with the 125I to form 125I-nimotuzumab and 125I-F(ab’)2-nimotuzumab. The radiochemical purity are 98.27 % and 93.24 %, respectively. Stability test results show that, both 125I-nimotuzumab and 125I-F(ab’)2-nimotuzumab are more stable at 4 °C than at room temperature storage and 37 °C.

Received: 24 May 2013; Revised: 21 February 2014; Accepted: 28 February 2014


Keywords


Fragmentation; Radiolabeling; 125I-F(ab’)2-nimotuzumab; 125I-nimotuzumab

Full Text:

PDF

DOI -


https://doi.org/10.17146/aij.2014.259



Copyright (c) 2016 Atom Indonesia

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.